11 Sep Dedicated Trialist, Nurse Navigators Help Advance Cancer Therapy Into Accelerated Approval
Thoracic medical oncologist Sally Lau, MD, considers herself a true trialist. She’s a clinician, yes, but takes immense pride and enjoyment in her role as an investigator in clinical trials. Recently, Lau spoke with Clinical Leader about her work on DeLLphi-304, studying the efficacy of tarlatamab (now marketed as Imdelltra), a bispecific T-cell engager therapy, as compared with standard-of-care treatments in patients with relapsed small-cell lung cancer (SCLC) after platinum-based first-line chemotherapy.
Lau discusses the FDA’s accelerated approval pathway in expanding care to patients with limited resources, how to accommodate and retain a challenging patient population, and her reasons for becoming — and remaining — a dedicated investigator. Read more…